■在人类患者中充分描述了经皮阿片渗透的解剖位置依赖性差异。虽然这已经在含有芬太尼的马匹中进行了调查,目前还没有关于经皮基质型贴剂给药时的位置依赖性血浆丁丙诺啡浓度的文献.
■本研究旨在比较放置在不同解剖部位(掌骨,加斯金,和腹尾基部)在健康的成年马中。
■这是一项具有拉丁方设计的随机实验研究。
■对六匹成年马进行三次处理,最少10天的清除期。对于每一种治疗,将两个20μgh-1基质型丁丙诺啡贴片应用于尾部基部的腹侧(TailTDP),掌骨区(掌骨TDP),或gaskin地区(GaskinTDP)。在施用贴剂之前(0小时)和之后0.5、2、4、6、8、10、12、16、24、32、48、56、72、96和120小时收集全血样品(用于测定丁丙诺啡浓度)和生理变量。放置后96小时去除斑块,并分析残留的丁丙诺啡含量。通过LC-MS/MS测量血浆中的丁丙诺啡浓度。使用混合效应模型来分析生理变量。
■在三个治疗组之间,与基线相比,以及单匹马和马之间的生理变量在不同时间点之间没有变化(p>0.3).当比较所有三个地点时,观察到丁丙诺啡的摄取与可测量的血浆浓度>0.1ngml-1更一致。在TailTDP组中,从2到32h,丁丙诺啡的平均血浆浓度>0.1ngml-1。最高组平均值为0.25ngml-1,在4h时记录。
■与尾基部的腹侧相比,掌骨和加斯金区的丁丙诺啡摄取和血浆浓度更加不稳定和不一致。进一步的研究必须针对研究最佳剂量,可达到的镇痛持续时间,可测量的血浆浓度的变化,以及行为和系统效应。
UNASSIGNED: Anatomical location-dependent differences in transdermal opioid penetration are well described in human patients. Although this has been investigated in horses with fentanyl, there is no literature available on location-dependent plasma buprenorphine concentrations when administered as a transdermal matrix-type patch.
UNASSIGNED: This study aims to compare the plasma concentrations achieved from the matrix-type transdermal buprenorphine patches placed at different anatomical sites (
metacarpus, gaskin, and ventral tail base) in healthy adult horses.
UNASSIGNED: This is a randomized experimental study with a Latin square design.
UNASSIGNED: Six adult horses were given each of three treatments with a minimum 10-day washout period. For each treatment, two 20 μg h-1 matrix-type buprenorphine patches were applied to the ventral aspect of the tail base (TailTDP),
metacarpus region (MetacarpusTDP), or gaskin region (GaskinTDP). Whole blood samples (for determination of buprenorphine concentration) and physiological variables were collected before (0 h) and at 0.5, 2, 4, 6, 8, 10, 12, 16, 24, 32, 48, 56, 72, 96 and 120 h after patches were applied. The patches were removed 96 h following placement and were analyzed for residual buprenorphine content. Buprenorphine concentrations were measured in plasma by LC-MS/MS. A mixed-effects model was used to analyze the physiological variables.
UNASSIGNED: Between the three treatment groups, there was no change in physiological variables across timepoints as compared to baseline and when compared to each other in a single horse and between horses (p > 0.3). When comparing all three locations, the buprenorphine uptake was observed to be more consistent with respect to measurable plasma concentrations >0.1 ng ml-1 when applied to the ventral aspect of the tail base. In the TailTDP group, the mean plasma buprenorphine concentrations were >0.1 ng ml-1 from 2 to 32 h. The highest group mean was 0.25 ng ml-1 noted at 4 h.
UNASSIGNED: The metacarpal and gaskin regions presented more erratic and inconsistent buprenorphine uptake and plasma concentrations as compared to the ventral aspect of the tail base. Further research must be directed at investigating the optimal dose, achievable duration of analgesia, change in measurable plasma concentrations, and behavioral and systemic effects.